Pharma Packaging and Labelling Compliance Conference

Fleming Europe23 - 25 March 2011, Barcelona, Spain.
As pharmaceutical and patient landscape is constantly developing worldwide, excellence in strategic packaging and labelling has become essential to regulatory compliance, patient adherence, safety and sustainability.

Fleming Europe has selected from across the globe the highest-level pharmapack specialists, who will share their many market-specific local interpretations, which will influence pharmaceutical packaging and labelling structurally in 2011.

Listen to them speaking about the latest regulations coming into effect in the next months (including PharmaBraille and 2D Datamatrix Marking System). Discover various ways of patient adherence and the business models of in-house vs. outsourced artwork management. Be part of interactive roundtables focusing on the most advanced technologies of pharmapack traceability.…and listen to real-life case studies of anti-counterfeiting, parallel trade and packaging sustanability.

This 3-Day-Event includes a target audience focused post-conference workshop in 2 streams, which will bring together innovative, responsible and cost-effective methods of pharmaceutical and medical packaging, addressing key labelling issues as well as creating partnerships between industry leaders.

Key speakers:

  • Executive Director, Healthcare Compliance Packaging Council (HCPC), Austria
  • Director, Global Regulatory Affairs Strategic Policy & Support, Johnson&Johnson, UK
  • Secretary General, Child-Safe Packaging Group, UK
  • Head of Packaging Strategy, Global Pharma Operations, Novartis, Switzerland
  • Head of Patient Information Quality, MHRA, UK
  • Director of Materials and Packaging Quality System, Eli Lilly, USA
  • Director of Healthcare Traceability, GS1 Global, UK
  • Head of Pharmacy Trade Sector, Roche Diagnostics, Germany

Key topics:

  • Packaging & Labelling Regulatory Updates
  • Patient Adherence
  • Excellence in Artwork Management: In-house vs. Outsourced
  • Traceability to Combat Non-compliance
  • Packaging suitable for the Blind – Braille-Guidelines according to the European standards implemented from October 2010
  • Innovative 2D Datamatrix System for Pharma Traceability
  • Anti-Counterfeiting using Advanced Technology
  • Parallel Traders Perspectives
  • Sustainable Packaging Innovations
  • Child-safe vs. Senior friendly Packaging – Balancing Patients’ Needs
  • Information based Packaging Redesign

Who should attend:
VPs, Directors, Heads and Managers of Packaging, Labelling, Supply Chain and Logistics, Regulatory Affairs and Compliance, Quality Assurance, Product Information, Product Development, Operations, Quality Control and Assurance, Licensing, Marketing and Sales, Patient Compliance, Purchase / Facilities, Manufacturing Technology, International Labelling Liaison, Packaging Designer, Global Labelling.

For further information and registration, please visit:
http://www.flemingeurope.com/life-science-conferences/europe/pharma-packaging-and-labelling-compliance-conference

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...